ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs MXN
16.53588
-0.12%
Brent Oil
83.115
-0.50%
Bitcoin
70,913.14
-0.75%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Verve Therapeutics Inc (VERV)

  7. Verve Therapeutics Inc (VERV) Noticias

VERV Verve Therapeutics Inc

5.95
0.00 (0.00%)
Pre Mercado
Última actualización: 04:22:45
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Verve Therapeutics Inc VERV NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 5.95 04:22:45
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
5.95
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/5/202406:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202406:15EDGAR2Form 8-K - Current report
08/5/202406:00GLOBEVerve Therapeutics Announces Pipeline Progress and Reports..
07/5/202406:00GLOBEVerve Therapeutics Announces Dosing of First Patient in..
03/5/202415:01GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
02/4/202406:00GLOBEVerve Therapeutics Announces Updates on its PCSK9 Program
28/3/202415:51GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
01/3/202415:01GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
27/2/202407:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202407:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202406:45EDGAR2Form 8-K - Current report
27/2/202406:30GLOBEVerve Therapeutics Provides Pipeline Progress and Reports..
16/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202405:30GLOBEVerve Therapeutics to Participate in the Guggenheim..
02/1/202405:30GLOBEVerve Therapeutics to Present at the 42nd Annual J.P. Morgan..
01/12/202315:00GLOBEVerve Therapeutics Announces Closing of Public Offering of..
29/11/202315:54EDGAR2Form 8-K - Current report
29/11/202315:47EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/11/202305:47DJNVerve Therapeutics Shares Tumble Premarket After Stock Sales
28/11/202321:37GLOBEVerve Therapeutics Announces Pricing of Public Offering of..
28/11/202315:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/11/202315:01GLOBEVerve Therapeutics Announces Proposed Public Offering of..
13/11/202305:34EDGAR2Form 8-K - Current report
12/11/202314:30GLOBEVerve Therapeutics Announces Interim Data for VERVE-101..
07/11/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:00EDGAR2Form 8-K - Current report
07/11/202305:30GLOBEVerve Therapeutics Highlights Recent Company Progress and..
31/10/202305:59DJNBeam Therapeutics to Sell Rights in Verve Licensing Deal to..
31/10/202305:01GLOBEVerve and Lilly Relationship Expands to Include Verve’s In..
23/10/202306:22DJNVerve Therapeutics Gets Clinical Hold For VERVE-101 Lifted..
23/10/202305:41EDGAR2Form 8-K - Current report
23/10/202305:30GLOBEVerve Therapeutics Announces Clearance of Investigational..
26/9/202305:30GLOBEVerve to Present Interim Data from the heart-1 Phase 1b..
21/9/202315:05GLOBEVerve Therapeutics to Participate in the 2023 Cantor Global..
18/9/202305:30GLOBEVerve Expands Leadership Team with Appointment of Frederick..
10/8/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202306:00EDGAR2Form 8-K - Current report
10/8/202305:30GLOBEVerve Therapeutics Highlights Recent Company Progress and..
03/8/202305:30GLOBEVerve Therapeutics to Present at the Canaccord 43rd Annual..
15/6/202306:16DJNVerve Therapeutics Strikes Gene Editing Deal With Eli Lilly
15/6/202305:30GLOBEVerve Establishes Global Collaboration with Lilly to Advance..
01/6/202305:30GLOBEVerve Therapeutics to Participate in the 2023 Jefferies..
23/5/202305:30GLOBEVerve Therapeutics to Participate in the Stifel 2023..

Su Consulta Reciente

NASDAQ
VERV
Verve Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados